Yashoda Hospitals > Medicine FAQS > Saroglitazar

Saroglitazar: Frequently Asked Questions Answered

What is Saroglitazar?

Saroglitazar (Trade name: Lipaglyn) is a recent drug developed to treat both type 2 diabetes mellitus and dyslipidemia. It is a dual regulator that corrects the imbalance in both the lipid profile and glycaemic indices. Saroglitazar plays a crucial role in controlling lipid and lipoprotein metabolism, glucose homeostasis, and inflammatory processes. This drug has an excellent clinical safety profile and higher efficacy in optimizing lipid and glycaemic targets.

What are the uses of Saroglitazar?

 Saroglitazar uses lies in treating major conditions like: 

  • Diabetic dyslipidemia (high cholesterol in diabetes).
  • Hypertriglyceridemia with type 2 diabetes mellitus uncontrolled by statin therapy.
  • Non-alcoholic fatty liver disease
  •  It lowers ‘bad’ cholesterol and fats (such as LDL, triglycerides).
  • It raises ‘good’ cholesterol levels (HDL). 

The drug has also shown promising anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.

    Enquire Now

    • Yes Same as WhatsApp number

    • By clicking on Send, you accept to receive communication from Yashoda Hospitals on email, SMS, call and Whatsapp.

    Book Doctor Appointment

    Book Appointment
    Book Online Doctor Appointment

    Online Video Consultation
    Search Specialty Doctor

    Find a Doctor
    Health Packages

    Health Packages

    What are the side effects of Saroglitazar?

    Saroglitazar does not usually create many side effects with the recommended dosage. Common side effects are:

    • Gastritis.
    • Asthenia (lack of energy).
    • Pyrexia.
    • Severe sweating and headache.
    • Dizziness.
    • Chest discomfort.

    Seek immediate medical attention if you develop severe symptoms. Get in touch with our medical experts at Yashoda Hospitals to learn more about the uses, dosages, and necessary precautions of Saroglitazar.

    What is Saroglitazar

    Uses of Saroglitazar

    Side effects of Saroglitazar

    References

    1. https://lipaglyn.com/downloads/Lipaglyn_Product_Monograph.pdf
    2. https://www.webmd.com/cholesterol-management/default.htm
    3. https://www.webmd.com/heart-disease/ldl-cholesterol-the-bad-cholesterol
    4. https://www.webmd.com/cholesterol-management/lowering-triglyceride-levels
    5. https://www.researchgate.net/publication/278244772_Saroglitazar_the_World’s_First_Drug_for_Treating_Diabetic_Dyslipidemia
    6. https://wileymicrositebuilder.com/progress/wp-content/uploads/sites/29/2016/05/Saroglitazar.pdf

    Disclaimer: The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.

    Need Any Medical Help?

    Talk to Our Health Care Experts!

    doctor avatar

    Need Any Medical Help?

    Have any Questions?

    Frequently Asked Questions about Saroglitazar

    Saroglitazar is generally a safe and well-tolerated drug. No severe adverse reactions were reported in Saroglitazar treatment. Overall there is no safety concern with the use of this drug. Use this drug as recommended by your consulting physician.

    The recommended dose of Lipaglyn-Saroglitazar is one tablet of 4 mg or 2mg once a day. Lipaglyn is available as uncoated tablets for oral administration. Each uncoated tablet of lipaglyn contains 4 mg of Saroglitazar.

    Fenofibrate is very effective at reducing triglyceride levels and increasing HDL cholesterol levels; however, it is less effective at lowering LDL cholesterol levels.

    Rosuvastatin effectively lowers cholesterol, but its long-term use may cause side effects such as muscle pain.

    Saroglitazar is advised to treat type 2 diabetes mellitus and dyslipidemia and is a good alternative for people who cannot tolerate statins.

    Each person with diabetes and high cholesterol has their own goals, needs, and preferences.

    Call Yashoda Hospitals and talk to our medical advisors to know which is the better medication for you.

    Yes, Saroglitazar helps in the management of high cholesterol, especially triglycerides. It can lower the high blood triglycerides and improve insulin resistance.

    No, Saroglitazar is not a statin. It is a non-statin drug approved for treating high triglycerides, type 2 diabetes mellitus, and dyslipidemia. They are the new generation of dual-action PPARs that provide a new approach to diabetes care, addressing hyperglycemia, dyslipidemia, and other metabolic syndromes. Saroglitazar is highly recommended for the treatment of diabetes dyslipidemia which couldn't manage statin therapy.

    Generally, Saroglitazar does not cause hypoglycemia. But in some patients, there may be hypoglycemic episodes where the patient needs to adjust the daily insulin dose with a consulting physician's help. Gradually the patient will be stable with controlled glycemic parameters.

    One can observe a slight decrease in body weight when under the treatment of Saroglitazar. An average 1.5 to 3 kg weight loss is observed when using Saroglitazar for 6-months. Likely, the amount of weight one loses is low and varies from person to person. If you experience drastic weight loss, please consult your physician. Patients who experience a rapid decrease in weight should immediately consult a physician.

    It is recommended that Saroglitazar be taken before the first meal of the day. Please take it as advised by your doctor in the prescribed dose. For more info, reach out to the team at Yashoda Hospitals.

    No, Saroglitazar is not a steroid. Saroglitazar is a novel dual PPAR α/γ agonist, non thiazolidinediones (TZD) and non-fibric acid derivative, with a predominant PPAR α agonistic activity, which helps in controlling the blood glucose and lipid parameters.

    Saroglitazar generally does not cause kidney damage. Clinical studies with Saroglitazar have not demonstrated any potential harm to renal function. But as a precaution, Saroglitazar treatment should be initiated with caution in patients with abnormal renal function.